The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 14.10 — safe zoneOK
- Earnings-manipulation signal · Beneish M -1.81 — no flag raisedOK
- Earnings quality 72/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as CATALYST PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Product Revenue Net$588.8M
- Firdapse$358.4M
- Agamree$117.1M
- Fycompa$113.3M
- License And Other Revenue$182K
Leadership changes
From CATALYST PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Molly Harper · Directors · appointment
- Charles B. O'Keeffe · Directors · appointment
- Donald A. Denkhaus · Directors · appointment
Latest filings
- 10-Q · Quarterly report2026-05-11
- 8-K · Company announcement2026-05-11
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-03-18
- 8-K · Company announcement2026-02-25
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about CATALYST PHARMACEUTICALS, INC., every answer cited🔒
- The Intelligence Brief — added when CATALYST PHARMACEUTICALS, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.